- $98.38m
- $83.15m
- $36.68m
- 54
- 41
- 46
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.09 | ||
| Price to Tang. Book | 1.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.4% | ||
| Return on Equity | -38.73% | ||
| Operating Margin | -99.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.78 | 31.3 | 36.89 | 41.42 | 36.68 | 38.06 | 46.8 | 15.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. The Company offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
Directors
- Paul Grossman CHM (60)
- Stephen Gunstream PRE (42)
- Matthew Lowell CFO (51)
- Lisa Hood CHO (40)
- Neal Goodwin CSO (56)
- Damon Terrill CCO (51)
- Irene Davis DRC (61)
- Ted Davis DRC (63)
- Alexander Herzick DRC (40)
- J. Matthew Mackowski DRC (66)
- Robert McNamara IND (64)
- Brett Robertson IND (61)
- Alexander Vos IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 7th, 2019
- Public Since
- June 25th, 2021
- No. of Shareholders
- 16
- No. of Employees
- 210
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 40,823,387
- Address
- 2451 Bert Drive, HOLLISTER, 95023
- Web
- https://www.teknova.com/
- Phone
- +1 8316371100
- Auditors
- Ernst & Young LLP
Upcoming Events for TKNO
Similar to TKNO
908 Devices.
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
Cerus
NASDAQ Global Market
FAQ
As of Today at 19:02 UTC, shares in Alpha Teknova are trading at $2.41. This share price information is delayed by 15 minutes.
Shares in Alpha Teknova last closed at $2.41 and the price had moved by +5.7% over the past 365 days. In terms of relative price strength the Alpha Teknova share price has underperformed the S&P500 Index by -14.64% over the past year.
The overall consensus recommendation for Alpha Teknova is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Alpha Teknova does not currently pay a dividend.
Alpha Teknova does not currently pay a dividend.
Alpha Teknova does not currently pay a dividend.
To buy shares in Alpha Teknova you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.41, shares in Alpha Teknova had a market capitalisation of $98.38m.
Here are the trading details for Alpha Teknova:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TKNO
Based on an overall assessment of its quality, value and momentum Alpha Teknova is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alpha Teknova is $5.50. That is 128.22% above the last closing price of $2.41.
Analysts covering Alpha Teknova currently have a consensus Earnings Per Share (EPS) forecast of -$0.77 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alpha Teknova. Over the past six months, its share price has outperformed the S&P500 Index by +3.9%.
As of the last closing price of $2.41, shares in Alpha Teknova were trading -11.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alpha Teknova PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alpha Teknova's management team is headed by:
- Paul Grossman - CHM
- Stephen Gunstream - PRE
- Matthew Lowell - CFO
- Lisa Hood - CHO
- Neal Goodwin - CSO
- Damon Terrill - CCO
- Irene Davis - DRC
- Ted Davis - DRC
- Alexander Herzick - DRC
- J. Matthew Mackowski - DRC
- Robert McNamara - IND
- Brett Robertson - IND
- Alexander Vos - IND